Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMW 2019 | Toxicities of MM drug treatments

Ravi Vij • 15 Sep 2019
IMW 2019
Multiple Myeloma Bortezomib Carfilzomib Lenalidomide Olanzapine Panobinostat Pomalidomide Selinexor Thalidomide

Ravi Vij, MD, MBA Washington University Medical School, St Louis, MO, discusses toxicities of multiple myeloma (MM) drug treatments and managing these side-effects, speaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Ravi Vij

MRD status by mass spectrometry with EasyM predicts outcomes following autoSCT in multiple myeloma
2:48
MRD status by mass spectrometry with EasyM predicts outcomes following autoSCT in multiple myeloma
Ravi Vij • 11 Dec 2023
Lenalidomide as post-autoSCT maintenance therapy for multiple myeloma
2:26
Lenalidomide as post-autoSCT maintenance therapy for multiple myeloma
Ravi Vij • 11 Dec 2023
Updated safety and efficacy results of ABBV-383, a novel BsAb, in patients with R/R multiple myeloma
3:23
Updated safety and efficacy results of ABBV-383, a novel BsAb, in patients with R/R multiple myeloma
Ravi Vij • 11 Dec 2023
Resistance to immunotherapy in multiple myeloma: mechanisms & monitoring
2:35
Resistance to immunotherapy in multiple myeloma: mechanisms & monitoring
Ravi Vij • 12 Dec 2022

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Ravi Vij • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Ravi Vij • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Ravi Vij • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Ravi Vij • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals